For instance, the use of CXCR4 antagonists, such as plerixafor and mavorixafor, to treat warts, hypogammaglobulinemia, infections, myelokathexis syndrome caused by GOF CXCR4 mutations results in significantly less wart and infection burden (87, 88). This evidence concerns the gene CXCR4 and infection.